When COVID-19 hit, the Scripps Health research group put the trial on pause to roll To results published in the November 2020 Diabetes Care. In hyperglycemia and a greater time in the target range of 70 to 250 mg/dL (3.9 to 13.9 mmol/L), according Compared with the usual care group, the CGM group had significantly lower mean glucose levels and percentage of time To physicians for insulin adjustments as needed. A diabetesĪdvanced practice nurse also reviewed daily glucose trends and provided recommendations Telemetry service, which notified bedside nurses of glucose alerts and trends. To a non-ICU floor to real-time CGM with the device ( n=57) or usual care ( n=53).ĬGM data were wirelessly transmitted from the bedside and monitored by the hospital's It randomized 110 adults with type 2 diabetes admitted Results from a trial of the Dexcom G6 CGM, launched at Scripps Mercy Hospital in Sanĭiego before the pandemic. Improved glycemic control in the non-ICU hospital setting was seen in preliminary ![]() Remains the standard of care in hospitalized patients, small trials in inpatient, non-ICU wards have found decreased hypoglycemia with CGM devices, according to an article published in the September 2020 Journal of Clinical Endocrinology & Metabolism. Toward that goal, while bedside point-of-care glucose testing However, the panel also said researchers must provide data to show that CGM improves On isolation with highly contagious infectious diseases, such as COVID-19. The guideline, published in SeptemberĢ020 by the Journal of Diabetes Science and Technology, strongly recommended that clinicians consider initiating CGM in the hospital to reduce nurse contact for point-of-care glucose testing and use of PPE for patients Of 24 international experts in the use of CGM. In April 2020, the Diabetes Technology Society organized a consensus guideline panel On the general wards, there is reason to expect potential benefit, particularly during While there isn't a large amount of data on using CGM in the hospital, especially He and other experts described current use of CGM in hospitals and the potential benefitsĪnd challenges of wider inpatient implementation. They're actually using it for caring for patients.” But now, multiple centers are using CGM-not necessarily for research. “Before COVID, there were just a few groups testing the technology in the Virtual Database for COVID-19 in Diabetes, online at. Pasquel, who has collected national and internationalĮxperiences including hospital CGM implementation through the Collaborative Open-Access “The devices are being used in more than 100 hospitals ![]() Where the devices may not be as reliable as in the outpatient setting.”īut with more hospitals adopting remote CGM, those answers may come sooner than was ![]() “We don't know if there are interfering medications or clinical scenarios “In the hospital, CGM devices are not approved yetīecause the acuity of illness of patients and exposure to other medications,” Professor of medicine in the division of endocrinology at Emory University School Making around insulin dosing without fingerstick testing, the devices are still notįDA approved for use in the hospital, noted Francisco J. While the factory-calibrated CGM devices are approved to inform outpatient decision Two types of CGM devices to hospitals: the Abbott FreeStyle Libre 14-day Flash Glucose It would not object to such use during the pandemic. Got the green light for in-hospital use in April 2020 when the FDA told manufacturers One of those technologies is real-time continuousįormerly confined to the outpatient setting except in the realm of research, CGM devices Trials into real-world hospital practice. To the novel coronavirus, some cutting-edge technology has jumped quickly from clinical Need to preserve personal protective equipment (PPE) and minimize risk of exposure The COVID-19 pandemic has created a climate of clinical creativity.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |